Super Bowl Ads Spotlight Weight-Loss Drugs and Health Care Disparities

During the 2026 Super Bowl, companies promoting weight-loss drugs are investing significantly in celebrity-filled advertisements to reach a vast audience. Notably, Novo Nordisk is featuring comedian Kenan Thompson in a 90-second spot for its new Wegovy pill, while telehealth company Ro is showcasing tennis star Serena Williams in its first Super Bowl ad. Hims & Hers Health is also participating, with a commercial narrated by rapper Common that highlights disparities in health care access. The advertising push reflects a broader trend towards direct-to-consumer marketing for GLP-1 weight-loss drugs, which have gained popularity among Americans seeking effective treatments for obesity.

Reuters

Novo Nordisk and Eli Lilly are the primary competitors in the GLP-1 weight-loss drug market. Novo's Wegovy pill, which contains the active ingredient semaglutide, has already seen strong demand, while Lilly's oral version, Zepbound, is expected to receive approval soon. The Super Bowl is considered an optimal platform for these companies to connect with consumers, as it attracts around 130 million viewers, according to Nielsen projections. Advertising slots during the event are highly coveted, costing up to $10 million for a 30-second spot.

Reuters

The messaging in Hims & Hers' ad, which asserts that "Rich people live longer," critiques the existing health care system that favors the wealthy. The ad features a montage of affluent individuals engaging in wellness practices, suggesting that access to quality health care is a privilege. Dan Kenger, chief design officer at Hims & Hers, describes the ad as a commentary on an intimidating health care culture. Critics argue that while the ad addresses real frustrations with health care access, it simplifies complex issues and positions Hims & Hers as a solution without addressing the underlying systemic problems.

(The) Atlantic

Serena Williams, who has lost 34 pounds using Ro's GLP-1 medication, emphasizes the positive impact of the drug on her health. In her Super Bowl ad, she shares her experience of feeling better and moving more easily since starting the treatment. Williams' endorsement highlights the growing trend of celebrities influencing public perception of weight-loss drugs, which has sparked both interest and concern regarding their accessibility and safety.

WalesOnline

The rise of telehealth platforms like Hims & Hers has raised questions about the safety and efficacy of compounded medications. The FDA has initiated investigations into Hims & Hers for selling compounded GLP-1 pills, which are not subject to the same regulatory scrutiny as traditional medications. Critics warn that these practices could lead to unsafe prescriptions and exacerbate health disparities. Despite these concerns, the demand for weight-loss drugs continues to grow, driven by both celebrity endorsements and a societal focus on wellness.

(The) Atlantic

The Super Bowl advertising blitz for weight-loss drugs underscores a significant shift in how health care is marketed in the U.S. While these ads aim to democratize access to treatments, they also reflect deeper issues within the health care system, including disparities in access and the commercialization of health. As companies navigate this complex landscape, the implications for consumer health and safety remain a critical concern.

(The) Atlantic